Leaflet GLYCLADA 30mg prolonged-release tablets


Indicated for: type 2 diabetes mellitus

Substance: gliclazide (sulfonylurea antidiabetic)

ATC: A10BB09 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Sulfonylureas)

Gliclazide is an antidiabetic medication from the sulfonylurea class, used to control blood sugar levels in patients with type 2 diabetes. It works by stimulating the pancreas to produce more insulin, thereby helping to lower blood sugar levels.

It is recommended as part of a treatment plan that includes a balanced diet, regular physical activity, and blood sugar monitoring. Gliclazide is effective in preventing diabetes-related complications, such as damage to small blood vessels (retinopathy, nephropathy).

Side effects may include hypoglycemia (excessive drop in blood sugar), nausea, dizziness, or weight gain. It is important for patients to follow the prescribed dosage and watch for signs of hypoglycemia, such as shaking, sweating, or confusion.

General data about GLYCLADA 30mg

  • Substance: gliclazide
  • Date of last drug list: 01-05-2026
  • Commercial code: W54001004
  • Concentration: 30mg
  • Pharmaceutical form: prolonged-release tablets
  • Quantity: 60
  • Product type: generic
  • Price: 21.25 RON
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

  • Manufacturer: KRKA, D.D., NOVO MESTO - SLOVENIA
  • Holder: KRKA, D.D., NOVO MESTO - SLOVENIA
  • Number: 10606/2018/04
  • Shelf life: 5 years

Pharmaceutical forms available for gliclazide

Concentrations available for gliclazide

  • 30mg
  • 60mg
  • 80mg
  • 90mg

Compensation lists for GLYCLADA 30mg KRKA

NHP 5 (C2) - Diabetes

Price

Copayment

Patient

21.25 RON

21.25 RON

0.00 RON